The effects of an alpha-2-adrenoceptor agonist, antagonist, and their combination on the blood insulin, glucose, and glucagon concentrations in insulin sensitive and dysregulated horses.

The research investigates the effects of two drugs, an agonist called detomidine and an antagonist called vatinoxan, on insulin, glucose and glucagon levels in horses. The results suggest that vatinoxan is effective in preventing an insulin increase and high blood glucose levels induced by detomidine in horses with insulin dysregulation.

Study Design and Objectives

• This study aims to understand how alpha-2-adrenoceptor agonists and antagonists influence insulin, glucose and glucagon levels in horses. Particularly, the researchers want to know how these drugs affect horses with and without insulin dysregulation. These conditions refer to either an insensitivity to insulin (insulin resistance) or abnormal insulin production, both of which can cause irregular blood glucose levels.
• The researchers specifically test the effects of detomidine, a sedative and alpha-2-adrenoceptor agonist, and vatinoxan, an antagonist. The experiment involves comparing the effects of these two drugs individually, in combination and against a saline control treatment.
• Horses with insulin dysregulation and without it were included in the study, with eight horses in each group. Their responses to the drug treatments are then assessed through regular blood sampling over an eight hour period.

Key Findings

• The results show that insulin levels increased two hours after the administration of detomidine in both groups of horses. Horses with insulin dysregulation also had higher insulin levels four hours after the treatment.
• Compared to the saline treatment, blood glucose levels were higher one and two hours after detomidine injection in both groups of horses. These levels decreased below the saline treatment’s levels at the four-hour mark.
• Glucagon, a hormone important for controlling blood glucose levels, decreased one hour after detomidine injection in insulin dysregulated horses and after one and two hours in other horses.
• Interestingly, the combination of detomidine and vatinoxan did not lead to the same increase in blood glucose and insulin levels as detomidine alone. This suggests that vatinoxan can prevent the hyperglycaemia (high blood sugar levels) and subsequent insulin increase that detomidine induces in horses with insulin dysregulation.

Conclusions

• The findings of this study could be significant for improving the medical management of horses that are resistant to insulin or produce abnormal insulin levels, particularly those that need to be administered sedatives like detomidine.
• By demonstrating that vatinoxan can help regulate insulin and blood glucose levels in these horses, the study points to potential avenues for new treatment strategies.